Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: BMS-754807|DRUG: trastuzumab (Herceptin®)
Sponsor: Bristol-Myers Squibb